Acorda Therapeutics Corporate Bonds and Leverage Analysis
ACORDelisted Stock | USD 16.20 0.40 2.41% |
Acorda Therapeutics holds a debt-to-equity ratio of 2.557. . Acorda Therapeutics' financial risk is the risk to Acorda Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Acorda Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Acorda Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Acorda Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Acorda Therapeutics' stakeholders.
For most companies, including Acorda Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Acorda Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Acorda Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Acorda |
Given the importance of Acorda Therapeutics' capital structure, the first step in the capital decision process is for the management of Acorda Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Acorda Therapeutics to issue bonds at a reasonable cost.
Acorda Therapeutics Debt to Cash Allocation
Many companies such as Acorda Therapeutics, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Acorda Therapeutics currently holds 190.9 M in liabilities with Debt to Equity (D/E) ratio of 2.56, implying the company greatly relies on financing operations through barrowing. Acorda Therapeutics has a current ratio of 1.68, which is within standard range for the sector. Note, when we think about Acorda Therapeutics' use of debt, we should always consider it together with its cash and equity.Acorda Therapeutics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Acorda Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Acorda Therapeutics, which in turn will lower the firm's financial flexibility.Acorda Therapeutics Corporate Bonds Issued
Understaning Acorda Therapeutics Use of Financial Leverage
Acorda Therapeutics' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Acorda Therapeutics' current equity. If creditors own a majority of Acorda Therapeutics' assets, the company is considered highly leveraged. Understanding the composition and structure of Acorda Therapeutics' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York. Acorda Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 118 people. Please read more on our technical analysis page.
Pair Trading with Acorda Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acorda Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acorda Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Acorda Stock
0.58 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.56 | BKRKF | PT Bank Rakyat | PairCorr |
0.49 | PPERY | Bank Mandiri Persero | PairCorr |
0.48 | PPERF | Bank Mandiri Persero | PairCorr |
0.48 | BKRKY | Bank Rakyat | PairCorr |
The ability to find closely correlated positions to Acorda Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acorda Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acorda Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acorda Therapeutics to buy it.
The correlation of Acorda Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acorda Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acorda Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acorda Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Acorda Stock
If you are still planning to invest in Acorda Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acorda Therapeutics' history and understand the potential risks before investing.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Money Managers Screen money managers from public funds and ETFs managed around the world |
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.